Comparative Pharmacology
Head-to-head clinical analysis: AZSTARYS versus QUILLIVANT XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZSTARYS versus QUILLIVANT XR.
AZSTARYS vs QUILLIVANT XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZSTARYS is a prodrug of dexmethylphenidate, a central nervous system stimulant. The exact mechanism of action in attention deficit hyperactivity disorder (ADHD) is unknown, but it is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space.
Extended-release oral suspension formulation of methylphenidate, a central nervous system stimulant that inhibits the reuptake of dopamine and norepinephrine into presynaptic neurons, increasing their synaptic concentrations. The exact therapeutic effect in ADHD is unknown but is thought to involve dopaminergic and noradrenergic pathways in the prefrontal cortex.
Initial: 39.2 mg oral once daily in the morning; titrate weekly by 19.6 mg increments as needed; maximum dose: 78.4 mg once daily.
Initial: 25 mg orally once daily in the morning; may increase weekly in 25 mg increments based on tolerability and response. Maximum: 75 mg once daily.
None Documented
None Documented
Serdexmethylphenidate: 1.5 hours; dexmethylphenidate: 3.5 hours. The terminal half-life of total dexmethylphenidate after AZSTARYS is approximately 6.5 hours, supporting once-daily dosing.
Approximately 4 hours; extended-release formulation provides therapeutic levels for ~12 hours.
Renal: 90% (primarily as metabolites, with 50-70% as the major metabolite (-)-phensuximide glucuronide). Fecal: <5%.
Primarily renal (approximately 60% as unchanged drug); fecal excretion accounts for <5%.
Category C
Category C
CNS Stimulant
CNS Stimulant